Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

SELL
$65.71 - $74.53 $52,436 - $59,474
-798 Reduced 17.32%
3,809 $264,000
Q2 2022

Jul 22, 2022

BUY
$72.62 - $79.98 $73,128 - $80,539
1,007 Added 27.97%
4,607 $357,000
Q1 2022

May 05, 2022

SELL
$61.48 - $73.72 $53,057 - $63,620
-863 Reduced 19.34%
3,600 $263,000
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $239,350 - $279,026
4,463 New
4,463 $278,000
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $335,198 - $392,641
-5,665 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$61.91 - $67.42 $11,453 - $12,472
185 Added 3.38%
5,665 $379,000
Q1 2021

May 10, 2021

BUY
$59.34 - $66.74 $13,944 - $15,683
235 Added 4.48%
5,480 $346,000
Q4 2020

Feb 05, 2021

BUY
$57.74 - $65.43 $87,533 - $99,191
1,516 Added 40.65%
5,245 $325,000
Q3 2020

Nov 05, 2020

SELL
$57.43 - $63.64 $148,169 - $164,191
-2,580 Reduced 40.89%
3,729 $225,000
Q1 2020

May 08, 2020

BUY
$46.4 - $67.43 $53,360 - $77,544
1,150 Added 22.29%
6,309 $352,000
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $51,375 - $67,014
1,044 Added 25.37%
5,159 $331,000
Q3 2019

Nov 13, 2019

BUY
$42.77 - $50.71 $175,998 - $208,671
4,115 New
4,115 $209,000
Q2 2019

Aug 12, 2019

SELL
$44.62 - $49.34 $196,997 - $217,836
-4,415 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $18,048 - $21,520
400 Added 9.96%
4,415 $211,000
Q4 2018

Feb 12, 2019

SELL
$48.76 - $63.23 $9,752 - $12,646
-200 Reduced 4.74%
4,015 $209,000
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $11,984 - $13,796
-200 Reduced 4.53%
4,215 $267,000
Q2 2017

Aug 11, 2017

BUY
N/A
4,415
4,415 $246,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Woodley Farra Manion Portfolio Management Inc Portfolio

Follow Woodley Farra Manion Portfolio Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodley Farra Manion Portfolio Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Woodley Farra Manion Portfolio Management Inc with notifications on news.